SLC30A7: A Potential Drug Target and Biomarker for Various Diseases

Target Name: SLC30A7

NCBI ID: G148867

SLC30A7

SLC30A7: A Potential Drug Target and Biomarker for Various Diseases

SLC30A7 (ZNT7-HUMAN), a member of the SLC30 family, is a zinc transporter that is expressed in various tissues and cells throughout the body. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SLC30A7 is a 21-kDa protein that is expressed in the brain, nervous system, and other tissues. It is involved in the transport of zinc, which is essential for various cellular processes, including cell signaling, DNA replication, and immune function. SLC30A7 is also involved in the regulation of pain perception and neurotransmitter release, and has been implicated in the development and progression of various neurological disorders.

SLC30A7 has been identified as a potential drug target due to its involvement in multiple cellular processes that are associated with various diseases. For example, SLC30A7 has been shown to be involved in the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, SLC30A7 has been shown to be involved in the regulation of cell signaling, DNA replication, and apoptosis. SLC30A7 has been shown to promote the growth and survival of cancer cells, and has been implicated in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancer.

In neurodegenerative diseases, SLC30A7 has been shown to be involved in the regulation of pain perception and neurotransmitter release. SLC30A7 has been shown to contribute to the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In autoimmune disorders, SLC30A7 has been shown to be involved in the regulation of immune function. SLC30A7 has been shown to contribute to the development and progression of autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, and lupus.

SLC30A7 has also been shown to be involved in the regulation of other cellular processes that are important for human health, including fetal development, tissue repair, and inflammation.

Due to its involvement in multiple cellular processes that are important for human health, SLC30A7 has potential as a drug target and biomarker for various diseases. SLC30A7 has been shown to be a promising target for the development of new treatments for cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, SLC30A7 (ZNT7-HUMAN) is a protein that is expressed in various tissues and cells throughout the body and is involved in the regulation of multiple cellular processes that are important for human health. As a potential drug target and biomarker, SLC30A7 has the potential to contribute to the development and treatment of various diseases. Further research is needed to fully understand the role of SLC30A7 in human health and to develop effective treatments for cancer, neurodegenerative diseases, and autoimmune disorders.

Protein Name: Solute Carrier Family 30 Member 7

Functions: Zinc ion transporter mediating zinc entry from the cytosol into the lumen of organelles along the secretory pathway (PubMed:15525635, PubMed:15994300). By contributing to zinc ion homeostasis within the early secretory pathway, regulates the activation and folding of enzymes like alkaline phosphatases (PubMed:15525635, PubMed:15994300)

The "SLC30A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC30A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets